Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal versus augmented level of replacement therapy study.
OBJECTIVE
To explore the relationship between timing of continuous renal replacement therapy commencement and clinical outcomes in critically ill patients with acute kidney injury. The primary outcomes were all-cause mortality at 28 and 90 days.


METHODS
Nested observational cohort study using data from the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study.


METHODS
Twenty-three ICUs in Australia and New Zealand.


METHODS
Four hundred thirty-nine critically ill patients with acute kidney injury Risk, Injury, Failure, Loss, End-stage kidney disease-injury (RIFLE-I) criteria.


METHODS
None.


RESULTS
The time between RIFLE-I acute kidney injury and randomization in the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study (proxy for continuous renal replacement therapy commencement) was the variable of interest. All baseline variables in the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study were assessed. Multivariable Cox, logistic, and linear regression models were used to assess the independent relationship of time of onset of RIFLE-I acute kidney injury and randomization and patient outcomes. The median time between RIFLE-I acute kidney injury and continuous renal replacement therapy commencement was 17.6 hours (interquartile range, 7.1-46 hr). Based on four groups of continuous renal replacement therapy commencement ([group 1; reference]: < 7.1, [group 2]: ≥ 7.1 to < 17.6, [group 3]: ≥ 17.6 to < 46.0, [group 4]: ≥ 46.0 hr), earlier commencement of continuous renal replacement therapy was not associated with a significantly lower risk of death at 28 days (hazard ratio for group 2: 1.06, 95% CI: 0.62-1.81; p = 0.83; hazard ratio for group 3: 1.23, 95% CI: 0.71-2.12; p = 0.46; hazard ratio for group 4: 1.33, 95% CI: 0.77-2.31; p = 0.31). Similar findings were observed for death at 90 days.


CONCLUSIONS
In a subgroup of participants of the Randomized Evaluation of Normal Versus Augmented Level Replacement Therapy Study, earlier commencement of continuous renal replacement therapy relative to RIFLE-I acute kidney injury was not significantly associated with improved survival. Additional studies with larger sample sizes and broader commencement times are warranted.
1The George Institute for Global Health, The University of Sydney, Sydney, NSW, Australia. 2Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG), Carlton, VIC, Australia. 3Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.
Min
M
Jun
Rinaldo
R
Bellomo
Alan
A
Cass
Martin
M
Gallagher
Serigne
S
Lo
Joanne
J
Lee
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058186:Acute Kidney Injury / Q000401:mortality / Q000628:therapy; D001315:Australia / Q000453:epidemiology; D015331:Cohort Studies; D016638:Critical Illness; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000628:therapy; D009520:New Zealand / Q000453:epidemiology; D011446:Prospective Studies; D017582:Renal Replacement Therapy / Q000401:mortality; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D016032:Randomized Controlled Trials as Topic